Unlabelled: . Effectiveness of oral nutritional supplements to prevent hospital malnutrition. Overview of systematic reviews.
Introduction: Although oral nutritional supplements (ONSs) are among most popular interventions to prevent a condition of hospital malnutrition, their real benefits need to be clarified.
Aim: To evaluate in adults the effectiveness of ONSs to prevent hospital malnutrition.
Methods: Papers retrieval by querying biomedical databases The Cochrane Library, Medline, Embase, CINAHL. Overview of systematic reviews evaluated for methodological quality according to R-AMSTAR checklist with narrative synthesis of results.
Results: Twenty-five systematic reviews met the inclusion criteria. Methodological quality was better in more recent studies. Low-moderate quality evidence showed a trend for decreasing mortality, complications, length of stay; there was no clear reduction in readmissions. Inadequate data do not allow to assess the impact on quality of life. The intervention seems promising for subjects over 75 years, malnourished, with pathological conditions of geriatric interest, in hospital or long-term care services, but differences are not always significant. The definition of malnutrition, screening procedures and assessment tools adopted varies widely, as well as the characteristics of participants, intervention and duration of studies included in systematic reviews; this makes difficult to estimate the net benefit due to ONSs.
Conclusions: The intervention should be included in a general approach to nutrition in clinical practice. At present the role of ONSs to prevent hospital malnutrition is still unclear.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1702/2890.29149 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.
Background: Effective early intervention of mild cognitive impairment (MCI) is the key for preventing dementia. However, there is currently no drug for MCI. As a multi-targeted neuroprotective agent, butylphthalide has been demonstrated to repair cognition in patients with vascular cognitive impairment, and has the potential to treat MCI due to Alzheimer's disease (AD).
View Article and Find Full Text PDFBackground: Patients with Alzheimer's disease (AD) often experience burdensome neuropsychiatric symptoms, including agitation which occurs in both home and long-term care (LTC) facilities, and is associated with substantial increases in caregiver burden and LTC placements. AXS-05 (45-mg dextromethorphan/105-mg bupropion), a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist, approved by the FDA for major depressive disorder, is being investigated for treatment of AD agitation (ADA). AXS-05 has been evaluated in 2 randomized, double-blind studies: Phase 2 ADVANCE-1 (NCT03226522); Phase 3 ACCORD (NCT04797715).
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
The George Institute for Global Health, University of New South Wales, Imperial College London, Sydney, NSW, Australia.
Background: Recent growth in the functionality and use of technology has prompted an increased interest in the potential for remote or decentralised clinical trials in dementia. There are many potential benefits associated with decentralised medication trials, but the field is currently lacking specific recommendations for their delivery in the dementia field.
Method: A modified Delphi method engaged a panel with substantial expertise in dementia trial design and delivery and backgrounds that included neurology, psychiatry, pharmacology and psychology, to develop recommendations for the conduct of decentralised medication trials in dementia prevention.
Background: The LatAm-FINGERS trial marks a pioneering initiative as the first non-pharmacological clinical trial encompassing participants from 12 Latin American countries, including Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Ecuador, Dominican Republic, Mexico, Peru, Puerto Rico, and Uruguay. This initiative represents a significant advancement in promoting inclusivity and diversity in clinical trial recruitment, particularly in underserved populations.
Method: The LatAm-FINGERS trial is a multicenter randomized clinical trial evaluating a lifestyle intervention tailored for the Latin American population.
Drug Development.
Alzheimers Dement
December 2024
Brigham and Women's Hospital and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
The most recent Alzheimer's clinical trials, including those which reported successful outcomes, use neuroimaging biomarkers of both amyloid and tau for screening participants and demonstrating a treatment effect on pathology. Some of these trials, notably Lecanemab, hint at a potential sex bias in treatment outcome, alluding to major implications for clinical practice when recommending treatment options. Sex differences in treatment response are not surprising given that women are at greater risk of progression to AD dementia, particularly if they carry APOEe4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!